{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4In_rJ0LDA","lastupdate":"2022-08-11T00:00:00.000Z","update_date":"2022-08-11T00:00:00.000Z","lastModified":"Aug 4, 2025","active":1,"confidence_score":92,"confidence_score_reason":"markets, not claimed","urlname":"revitalvision","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$QxdUYj0SwTIkUFN6SYqeFF3GYdVSyCuGLqbbyYgqGriKL9skmSg049","name":"RevitalVision","oneliner":"Neurological Treatment for Vision Disorders","registrar":"514246677","website":"https://www.revitalvision.com/","careerspage":"","founded_month":12,"founded_year":2019,"formernames":[],"sociallinks":{"twitter":"https://twitter.com/REVITALVISION","youtube":"https://www.youtube.com/channel/UC27jcy7ZOvvXxB7XomQ_Kcw","facebook":"https://www.facebook.com/RevitalVision-114518368626151","linkedin":"https://www.linkedin.com/company/1577762","instagram":""},"social":["https://twitter.com/REVITALVISION","https://www.youtube.com/channel/UC27jcy7ZOvvXxB7XomQ_Kcw","https://www.facebook.com/RevitalVision-114518368626151","https://www.linkedin.com/company/1577762"],"flattenedsociallinks":"https://twitter.com/REVITALVISION|https://www.youtube.com/channel/UC27jcy7ZOvvXxB7XomQ_Kcw|https://www.facebook.com/RevitalVision-114518368626151|https://www.linkedin.com/company/1577762","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"11-50","employees_exact":17,"patent":1,"raised":3700000,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Revital.Vision","Revital-Vision","Revital Vision","TALSHIR GUY MEDICAL TECHNOLOGIES"],"about":"RevitalVision is a SaaS-based digital health startup operating in the rapidly growing, $52 billion field of vision improvement in the ophthalmic marketplace. The company’s noninvasive technology enhances eyesight neurologically, offering an innovative solution to the 500 million people whose needs are unmet by existing vision treatments. \n\nRevitalVision’s thousands of clinical trial participants and commercial customers have reported and exhibited significant improvement in their vision performance by 2.5 lines on the visual acuity eye chart along with a 100% increase in contrast sensitivity on average for all product categories. \n\nRevitalVision is FDA-cleared for children older than 9 and adults with amblyopia (lazy eye), a leading cause of vision impairment that affects 3% to 5% of the world population. Using brain science and proprietary algorithm-based technology, RevitalVision is clinically validated for use for multiple eye diseases and vision impairments and has been approved for two new unique reimbursement codes by the American Medical Association for the treatment of amblyopia. \n\nRevitalVision provides eye care specialists with a simple, easy-to-use tool to improve patients’ vision beyond optical correction and other current eye treatments, as well as an additional revenue channel. The company also offers eye surgery clinics a valuable tool for reducing unpaid post-surgery visits by cataract and refractive patients who find it difficult to neuro-adapt or who suffer from reduced contrast sensitivity, poor night vision, or side effects such as halo and glare.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+972772123272","country":null,"address":{"israeli":[{"id":"f6f9dbaa-2655-43b2-80a0-f2d14858b33d","city":"Modi'in-Maccabim-Re'ut","type":null,"address":"HaMa'ayan Street 2, Modi'in-Maccabim-Re'ut, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"6qhbWW4qKTwQLglyvzDx27o6mbTBmItyOFyfLTCD30lfQWufS797Z8","date":"Apr 15, 2024","link":"https://en.globes.co.il/en/article-revitalvision-announces-success-in-new-trial-1001476519","source":"en.globes.co.il","visible":1,"analysis":{"tags":"Healthcare, Eye Treatment","company":"RevitalVision","layoffs":"Not mentioned","summary":"RevitalVision, a company that develops products to treat eye conditions by retraining the brain, has announced successful trials of a product for improving vision through visual stimulation. The product was tested for the treatment of nystagmus and keratoconus, conditions that affect eye movement and shape respectively. The companys products are already approved for the treatment of lazy eye syndrome. RevitalVision was founded in 2019 and has raised $4 million, partly through crowdfunding. The success of the new studies will assist the company in its marketing activity in the professional community.","partners":"Not mentioned","customers":"Not mentioned","investors":"Crowdfunding","confidence":9,"key_topics":["Eye Treatment","Clinical Trials","Investment","Marketing","Product Success"],"date_of_event":"April 15, 2024","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$4 million","structured_issues":["Investment","Customers"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"1dB8kihfOBHh0TCTLzIkA12xtvMv6Hgsmf13XaVIfsXOf0Uc7DOa6E","news_summary":"RevitalVision announces success in new trial","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"748df5de-23d6-4d61-a675-2a643d7c1e89","date":"Oct 11, 2021","link":"https://www.geektime.co.il/non-invasive-eye-treatment-2/","source":"www.geektime.co.il","visible":1,"analysis":{"tags":"Investment, Expansion","company":"RevitalVision","layoffs":"N/A","summary":"Israeli startup RevitalVision, which has developed technology to improve vision, has raised over 3.2 million shekels in its second funding round. The companys technology, which is clinically proven, improves image processing in the brain rather than treating the eye. The company has over 340 investors and has recently received a treatment code in the US, a necessary step for insurance coverage in the country. The company has treated over 10,000 customers with its technology and is the only product with FDA efficiency approval for improving vision in lazy eye in adults.","partners":"N/A","customers":"Over 10,000","investors":"340 private investors","confidence":9,"key_topics":["Investment","Vision Improvement Technology","Clinical Research","FDA Approval","Expansion"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"3.2 million shekels","structured_issues":"Investment, Expand","acquisition_amount":"N/A","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"0X6wft01qP79YKoBcCUcS8dAO7Kk2szVgUgxB4RIsAzPuDL2zmS4OI","news_summary":"רגע לפני הפריצה לארה\"ב: סבב גיוס שני לסטארטאפ ישראלי שפיתח טכנולוגיה לשיפור הראייה","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"d53016b1-9a7b-4d23-bb0b-46183470fb30","date":"Jul 18, 2021","link":"https://www.globes.co.il/news/article.aspx?did=1001378510","source":"www.globes.co.il","visible":1,"analysis":{"tags":"FDA approval, reimbursement code","company":"RevitalVision","layoffs":"Not mentioned","summary":"Israeli company RevitalVision has received FDA approval and a specific reimbursement code in the US for its vision training software developed for the treatment of lazy eye in adults and children over the age of 9. The code will be effective from January 2022 and will allow doctors using the companys technology to collect payment for treatment using the product. The company recently raised $1 million through the PeopleBiz crowdfunding platform and is in the process of raising an additional $4 million.","partners":"Not mentioned","customers":"Not mentioned","investors":"Concord, Shamrock, PeopleBiz","confidence":8,"key_topics":"FDA approval, vision training software, lazy eye treatment, reimbursement code, funding","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$1 million","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"yhOR16CnMnZcqe07pJrkYCiVHDTIUCXsgcy5InmPPM8urF6WtM33Zu","news_summary":"אישור FDA וקוד שיפוי ביטוח לחברת רויטל ויז'ן המטפלת בעין עצלה","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"5c9104f2-5256-4121-aa77-0d80e4e2b1a5","date":"Mar 21, 2021","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3900592,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"vision training","company":"RevitalVision","layoffs":null,"summary":"RevitalVision, an Israeli vision training company, is preparing to launch its technology in the American and European markets. The companys technology stimulates the brains visual cortex to improve vision without invasive surgery. It is FDA-approved and specifically targets amblyopic adults, who make up 3% of the population. RevitalVision has applied for a unique CPT code from the American Medical Association to enter the American healthcare system and receive reimbursement from insurance carriers. The company has already helped thousands of people achieve significant improvements in vision and quality of life. The technology has been successful in enabling individuals to pass vision tests and gain drivers licenses and admission to IDF pilot courses.","partners":null,"customers":null,"investors":null,"confidence":9,"key_topics":["lazy eye","vision improvement","brain stimulation","FDA approval","expansion into American and European markets"],"date_of_event":"21.03.21","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"fIR3W3yQv3gvlnexJEBcgpSgthYgFLc1vAOGl73rk6bQ56DfziV5KM","news_summary":"Israel's RevitalVision expands its vision technology to U.S and Europe","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"7077ebac-3599-4116-ba07-645d7e010d11","date":"Oct 1, 2011","link":"https://www.healio.com/news/optometry/20120225/home-based-software-offers-physical-therapy-for-the-eyes","source":"www.healio.com","visible":1,"analysis":{"tags":"Healthcare, Technology","company":"RevitalVision LLC","layoffs":"N/A","summary":"RevitalVision LLC, a company based in Lawrence, Kansas, has developed a computer-based vision therapy program that can be used by patients at home after undergoing LASIK and cataract surgery. The program, which is customized to the patients pace and visual ability, is monitored by a personal RevitalVision specialist. The length and duration of the program vary by patient and specific need. The program has shown to improve visual outcomes and patient satisfaction, with patients showing an objective improvement in Snellen acuity of 1.5 to 2.0 lines.","partners":"N/A","customers":"Patients after LASIK and cataract surgery, those with presbyopia or amblyopia","investors":"N/A","confidence":9,"key_topics":["Ocular Surgery","Vision Therapy","Computer Program","Patient Satisfaction","Visual Performance"],"date_of_event":"October 01, 2011","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":"Customers","acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"lXX5OPe8U7HRQa6UD76ovmYu4nxWmhi6FAO2gCTPXx7QYbK7mPIXFl","news_summary":"Home-based software offers physical therapy for the eyes","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":5,"techcommunityinvolvement":null,"mediagallery":[{"id":"72ea1f0b-a1ad-4c96-be54-66797d7d6a4c","timestamp":"2020-08-13 08:56:09.000000","resources_type":2,"resources_title":"Throw away your glasses - RevitalVision","resources_file_name":"Zp1wEXQMjJg","alt":"Throw away your glasses - RevitalVision logo","imageurl":"https://img.youtube.com/vi/Zp1wEXQMjJg/0.jpg","url":"http://youtu.be/Zp1wEXQMjJg"}],"tags":["algorithms","artificial-intelligence","personalization","non-invasive","telemedicine","athletes","clinics","diagnostics","computer-vision","home-care","doctors","seniors","patients","non-surgical","visually-impaired","eye-diseases","digital-healthcare"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-u8oJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nqIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81bgJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvT54kLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Released","products":[],"geomarkets":["Americas","United States","Asia","Europe"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":1,"lastfunding":"$500K","totalrounds":3,"fundingstage":"Seed","totalfunding":"$3.7M","publicinvestors":1,"lastpublicfunding":500000,"totalpublicrounds":3,"totalpublicfunding":3700000},"team":[{"name":"Yair (Gottlieb) Yahav","email":"yair@revitalvision.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4KnH36AIDA","bounced":false,"claimed":1,"founder":1,"urlname":"yair-yahav","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgycez3QsM","position":"CEO","last_name":"(Gottlieb) Yahav","claimtoken":"lsC6LxHDzQxCEFTofk1l8QqAQVoEpDDJBv82nOvYe71sZM2asZzfjg","first_name":"Yair","picturekey":null,"claimeddate":"2023-02-17","linkedinurl":"https://www.linkedin.com/in/yairyahav/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-02-13 12:55:33.000000","initials":"Y(","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yogev Shamay","email":"yogev@revitalvision.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Kmm87AJDA","bounced":false,"claimed":0,"founder":0,"urlname":"yogev-shamay","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgifOC6goM","position":"CTO & Cofounder ","last_name":"Shamay","claimtoken":"fDBFrHSKDzJAkneOBqcBuvXL1wyhId9sQlA6LVSfpc8mWONaWtZHQl","first_name":"Yogev","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yogev-shamay-a7640573/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-02-13 12:55:36.000000","initials":"YS","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yuval Ron-Ruhama","email":"yuval@revitalvision.com","phone":"","gender":"Male","userid":"iA3YI0H75JErl9q8t8YyBU355UK0g3WHzIYyFfP6ykmx1gR4gTSed5","bounced":false,"claimed":null,"founder":0,"urlname":"yuval-ron-ruhama-2","visible":1,"memberid":"3oXzjcBzUzTBQ1gCWi9OWbyc1sszruXlmAJ7zrn7UXWYbez4z1A12e","position":"COO","last_name":"Ron-Ruhama","claimtoken":null,"first_name":"Yuval","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yuval-ron-ruhama-78109034/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"YR","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Rona Erlich","email":"rona@revitalvision.com","phone":"","gender":"Female","userid":"CVTYQTHxOYA0nFpF1ZEZmRJBKRlpnvGwcOB4fjQTAdChNWRBc96D54","bounced":false,"claimed":null,"founder":0,"urlname":"rona-erlich","visible":1,"memberid":"3BnAMXpYRx8d38Pjx4dSZZwK1J4rXOkP18PQIXOGDhwdQPdhDkpahJ","position":"Marketing Director","last_name":"Erlich","claimtoken":null,"first_name":"Rona","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/ronaerlich/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"RE","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yariv Baron","email":"yariv@revitalvision.com","phone":"","gender":"Male","userid":"RUB24gBJYO0l8uy3EcPf0rdrBu1FtYdMjEbaEAYX7SQY9jIp4M4iTE","bounced":false,"claimed":null,"founder":0,"urlname":"yariv-baron","visible":1,"memberid":"JcRRvyBxG7DQrrT4RtcLNtHYgzrWmFsBDskRKbr9CSDemFl0qTWztp","position":"Director","last_name":"Baron","claimtoken":null,"first_name":"Yariv","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yariv-bar-on-203b7924/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"YB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNqyo8cLDA","fullname":"Yotam Maman"},"biverifydate":"2020-08-13T00:00:00.000Z","crunchbaseid":"","lastupdator":"Yanina Wainscheinker","lastupdator_email":"yanina.wain@gmail.com","creator":"Yotam Maman","creator_email":"yotamm1988@gmail.com","createdate":"2020-08-13T00:00:00.000Z","biverification":"Yotam Maman","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"a3zpP8APpSsFJKRg42wAjfVMaf7ZQlwp7RiuZo72iYpWpZueNS59r5","hub":"Margalit Startup City Haifa","date":"Nov 2022","batch":"1","amount":"Undisclosed","hub_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkLjosJEIDA","source":"https://www.maariv.co.il/business/tech/Article-961002?_atscid=7_134353_204082920_2315865_0_Txtetaxjxdshwhus8sp","enddate":"Nov 2022","hub_type":"Accelerator","eventtype":"GraduationEvent","hub_hidden":false,"investment":[],"hub_fullurl":"/program_page/margalit-startup-city-haifa","hub_logokey":null,"hub_urlname":"/program_page/margalit-startup-city-haifa","eventvisibility":null,"amountvisibility":null,"fundingvisibility":null,"style":"","hiddenCompanyTooltip":"","hub_logourl":"/assets/empty-state.svg","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"rQzNpDE2j9iyjCV7CaVszDvOni0U0hEuAJ4HJyF8rw4w16pORDIrmY","date":"Jun 2021","amount":"$500K","source":"","eventtype":"GrantEvent","granttype":1,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"rLPetBDL9GqIc8FTAOtBnxRDVeRHWuyGPq5eOxyi30v6bD7FWQZKf3","date":"Jun 2021","amount":"$500K","source":"","eventtype":"GrantEvent","granttype":1,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDgvNCeCgw","date":"May 2021","amount":"$2.7M","source":"https://pipelbiz.com/Campaign/52830","eventtype":"FundingRoundEvent","investment":[{"name":"PipelBiz","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/pipelbiz1","logokey":"$ocacoMAaDuAtaYoIeEPZvVmHRZpgx3q16TgzdfhnNGFg6uLU278dLM","tagline":null,"urlname":"/investor_page/pipelbiz1","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Oy5s7QIDA","fundingtype":"Equity Crowdfunding","leadpartner":null,"investmentid":"czhjyWUzJdYSn4Fdq3vqdCcll0zheeowH4kPoPK92uZDVR4q8XkRmN","fundingsubtype":"Equity Crowdfunding","investorislead":1,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ocacoMAaDuAtaYoIeEPZvVmHRZpgx3q16TgzdfhnNGFg6uLU278dLM","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Equity crowdfunding","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"12/2019","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"RevitalVision","logourl":"https://storage.googleapis.com/clean-finder-353810/$QxdUYj0SwTIkUFN6SYqeFF3GYdVSyCuGLqbbyYgqGriKL9skmSg049","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$QxdUYj0SwTIkUFN6SYqeFF3GYdVSyCuGLqbbyYgqGriKL9skmSg049","seoabout":"RevitalVision is a SaaS-based digital health startup operating in the rapidly growing, $52 billion field of vision improvement in the ophthalmic marketplac...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":5,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Digital Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81bgJDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":2,"name":"Computer Vision","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":1,"name":"Consumers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Recreational & Lifestyle","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nqIKDA","classificationName":"targetcustomer"},{"depth":3,"name":"Fitness & Sports","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-u8oJDA","classificationName":"targetcustomer"},{"depth":2,"name":"Demographics & Family","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Seniors","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvT54kLDA","classificationName":"targetcustomer"}],"classificationDelimited":["SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Recreational & Lifestyle#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nqIKDA>Fitness & Sports#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-u8oJDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA>Computer Vision#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Recreational & Lifestyle#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nqIKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA>Digital Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81bgJDA","IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA>Seniors#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvT54kLDA","TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA"],"classificationsViewModel":"|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Digital Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA/Digital Therapeutics#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81bgJDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Providers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA|1:>IndustryClassificationModel/Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA|2:>IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA/Recreational & Lifestyle#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nqIKDA|3:>IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Recreational & Lifestyle#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nqIKDA/Fitness & Sports#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-u8oJDA|2:>IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA/Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA|3:>IndustryClassificationModel>Consumers#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA>Demographics & Family#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA/Seniors#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvT54kLDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA|2:>TechnologyClassificationModel>Artificial Intelligence#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA/Computer Vision#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Digital Healthcare","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare","children":[{"title":"Digital Therapeutics","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Digital Healthcare>Digital Therapeutics"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"},{"title":"Providers","key":"0-0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Providers"}]}]},{"title":"Consumers","key":"0-1","path":"IndustryClassificationModel>Consumers","children":[{"title":"Recreational & Lifestyle","key":"0-1-0","path":"IndustryClassificationModel>Consumers>Recreational & Lifestyle","children":[{"title":"Fitness & Sports","key":"0-1-0-0","path":"IndustryClassificationModel>Consumers>Recreational & Lifestyle>Fitness & Sports"}]},{"title":"Demographics & Family","key":"0-1-1","path":"IndustryClassificationModel>Consumers>Demographics & Family","children":[{"title":"Seniors","key":"0-1-1-0","path":"IndustryClassificationModel>Consumers>Demographics & Family>Seniors"}]}]}],"coreTechnology":[{"title":"Artificial Intelligence","key":"0-0","path":"TechnologyClassificationModel>Artificial Intelligence","children":[{"title":"Computer Vision","key":"0-0-0","path":"TechnologyClassificationModel>Artificial Intelligence>Computer Vision"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Digital Healthcare","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah6ILDA","classificationName":"sectorclassification"},{"depth":3,"name":"Digital Therapeutics","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu81bgJDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Artificial Intelligence","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu1rJEIDA","classificationName":"coretechnology"},{"depth":2,"name":"Computer Vision","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEKDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Providers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4JvZ7tMLDA","classificationName":"targetcustomer"},{"depth":1,"name":"Consumers","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu18NgKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Recreational & Lifestyle","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nqIKDA","classificationName":"targetcustomer"},{"depth":3,"name":"Fitness & Sports","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-u8oJDA","classificationName":"targetcustomer"},{"depth":2,"name":"Demographics & Family","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Pvo8q4JDA","classificationName":"targetcustomer"},{"depth":3,"name":"Seniors","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvT54kLDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Digital Healthcare","Digital Therapeutics"],"coreTechnology":["Artificial Intelligence","Computer Vision"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Patients","Providers","Consumers","Recreational & Lifestyle","Fitness & Sports","Demographics & Family","Seniors"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgJDgvNCeCgw","date":"May 2021","amount":"$2.7M","source":"https://pipelbiz.com/Campaign/52830","eventtype":"FundingRoundEvent","investment":[{"name":"PipelBiz","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/pipelbiz1","logokey":"$ocacoMAaDuAtaYoIeEPZvVmHRZpgx3q16TgzdfhnNGFg6uLU278dLM","tagline":null,"urlname":"/investor_page/pipelbiz1","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4Oy5s7QIDA","fundingtype":"Equity Crowdfunding","leadpartner":null,"investmentid":"czhjyWUzJdYSn4Fdq3vqdCcll0zheeowH4kPoPK92uZDVR4q8XkRmN","fundingsubtype":"Equity Crowdfunding","investorislead":1,"amountvisibility":null,"isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":null,"leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ocacoMAaDuAtaYoIeEPZvVmHRZpgx3q16TgzdfhnNGFg6uLU278dLM","leadcaption":"Lead ","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Equity crowdfunding","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[{"id":"rQzNpDE2j9iyjCV7CaVszDvOni0U0hEuAJ4HJyF8rw4w16pORDIrmY","date":"Jun 2021","amount":"$500K","source":"","eventtype":"GrantEvent","granttype":1,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"rLPetBDL9GqIc8FTAOtBnxRDVeRHWuyGPq5eOxyi30v6bD7FWQZKf3","date":"Jun 2021","amount":"$500K","source":"","eventtype":"GrantEvent","granttype":1,"investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":null,"isjointventuregrant":0,"fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Non-Equity Funding","isgrant":true,"isicoevent":false,"amountnumber":500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"merger_acquisitions":[],"others":[]}}